Autonomix Medical, Inc. (NASDAQ: AMIX), a trailblazer in medical device technology focused on neurological conditions, has seen its stock soar over 100% today following a major licensing agreement. The company announced a definitive agreement with RF Innovations, Inc., a leader in medical technology, to license the intellectual property of the Apex 6 Radiofrequency Generator—an FDA-cleared ablation technology for pain management in the peripheral nervous system.
Strategic Move to Expand Technological Capabilities
This significant transaction involves the transfer of 250,000 shares of common stock in exchange for a perpetual, non-exclusive, worldwide, royalty-free license of the Apex 6 Generator IP. This move is not just a licensing agreement but a strategic acquisition of technology that enhances Autonomix’s existing portfolio. The Apex 6 Generator will be integrated with Autonomix’s innovative sensing devices, aimed at revolutionizing the diagnosis and treatment of diseases involving the nervous system.
Comments from Leadership
Brad Hauser, President and CEO of Autonomix, expressed his enthusiasm about the acquisition: “This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management,” he noted. Hauser also highlighted the strategic fit of the Apex 6 technology with Autonomix’s novel sensing device, which is expected to expedite the company’s development timeline.
Collaborative Efforts and Future Prospects
The collaboration with RF Innovations extends beyond the licensing agreement. RF Innovations will also assist Autonomix by incorporating their manufacturing partner into Autonomix’s supply chain, facilitating the development of the integrated equipment. This partnership underscores a shared vision between the two companies to push the boundaries of medical technology.
Autonomix is initially targeting the technology for the management of pancreatic cancer-related pain, a notoriously difficult condition to treat effectively with current options like opioids and invasive procedures. The company plans to explore further indications based on the initial data from this application.
About Autonomix Medical, Inc.
Autonomix Medical, Inc. is at the forefront of developing cutting-edge medical devices aimed at transforming the way diseases of the nervous system are diagnosed and treated. Their pioneering technology platform includes a catheter-based microchip sensing array, which offers unprecedented sensitivity in detecting and differentiating neural signals. This technology has the potential to enable transvascular diagnosis and treatment of peripheral nervous system diseases—a first in medical technology.
While still investigational and awaiting FDA clearance for marketing in the United States, Autonomix’s technology promises to redefine pain management and potentially treat a variety of conditions across multiple medical fields including cardiology and chronic pain management.
